| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Valproate(VPA) is an anti-epileptic agent with abilities of a histone deacetylase inhibitor (HDACi) which enhances immune response. Recent studies suggest that VPA is associated with improved survival in glioblastomas (GBMs). We examined the immunological mechanisms of VPA against GBMs. VPA emphasized the cytotoxic activity against GBM cell line by stronger expression of immune related surface markers like major histocompatibility complex (MHC) class I resulted in enhanced expression of glioma antigens.
Moreover, we examined the influence of VPA against the methylation of O6-methylguanin-DNA-methyltransferase (MGMT) promotor by pyrosequence analysis. In our study, VPA did not have adverse influence of temozolomide resistant activity in GBMs. Taken together, we suggested that VPA might be recommended to use for combined therapy of temozolomide and immunotherapy against GBMs.
|
